Document Detail

Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure).
MedLine Citation:
PMID:  17700397     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Excess aldosterone activity contributes to the pathogenesis and progression of heart failure (HF). Aldosterone antagonists improve clinical outcome in patients with severe HF or left ventricular (LV) dysfunction after myocardial infarction, but knowledge of their impact in mild chronic HF is sparse. AREA IN-CHF was planned to investigate the effects of canrenone on progression of LV remodelling in mild HF. METHODS: AREA IN-CHF is a multicentre, randomised, double-blind, parallel group comparison of canrenone (up to 50 mg/day) versus placebo in mild stable HF. The primary endpoint is change in echocardiographic LV end-diastolic volume over 12 months. Patients had New York Heart Association class II HF, LV ejection fraction < or =45%, stable standard therapy, creatinine < or =2.5 mg/dl, potassium < or =5.0 mmol/l. Follow-up examinations were scheduled monthly for the first 3 months and every 3 months thereafter. Aldosterone was measured at baseline, brain natriuretic peptide and procollagen type III amino-terminal peptide (PIIINP) at baseline and at 6 months. Echocardiography was performed at baseline, at 6 and 12 months. RESULTS: Among 467 patients, median age 64 years (interquartile range (IQR) 56-70 years), 84% were men, 52% had ischaemic HF, 96% were receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, 79% beta-blockers. Brain natriuretic peptide, aldosterone and PIIINP were 88 pg/ml (IQR 35-185 pg/ml), 118 pg/ml (IQR 75-177 pg/ml), and 5.38 microg/l (IQR 3.98-7.14 microg/l), respectively. LV end-diastolic volume was 79 ml/m (IQR 64-105 ml/m) and LV ejection fraction was 40% (IQR 33-45%). CONCLUSIONS: The role of aldosterone blockade in patients with mild HF remains to be established. AREA IN-CHF is addressing this issue in a large population on optimal medical therapy.
Alessandro Boccanelli; Giuseppe Cacciatore; Gian Francesco Mureddu; Giovanni de Simone; Francesco Clemenza; Renata De Maria; Andrea Di Lenarda; Antonello Gavazzi; Roberto Latini; Serge Masson; Maurizio Porcu; Massimo Vanasia; Lucio Gonzini; Aldo Pietro Maggioni
Related Documents :
20675667 - Cardiac remodelling and myocardial recovery: lost in translation?
9236147 - Left ventricular regional myocyte contractility in normal and heart failure states.
7148647 - Hemodynamic and myocardial energetic changes induced by the new cardiotonic agent, ar-l...
15363827 - Association of inappropriate left ventricular mass with systolic and diastolic dysfunct...
6461707 - Repolarization abnormalities of left ventricular hypertrophy. clinical, echocardiograph...
21310317 - Cardiac resynchronization therapy is more effective in women than in men: the madit-crt...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of cardiovascular medicine (Hagerstown, Md.)     Volume:  8     ISSN:  1558-2027     ISO Abbreviation:  J Cardiovasc Med (Hagerstown)     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2007-08-16     Completed Date:  2007-10-25     Revised Date:  2009-05-28    
Medline Journal Info:
Nlm Unique ID:  101259752     Medline TA:  J Cardiovasc Med (Hagerstown)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  683-91     Citation Subset:  IM    
Department of Cardiology, San Giovanni Addolorata Hospital, Rome, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aldosterone / blood
Aldosterone Antagonists / pharmacology,  therapeutic use*
Biological Markers / blood
Canrenone / pharmacology,  therapeutic use*
Disease Progression
Double-Blind Method
Heart Failure / blood,  drug therapy*,  ultrasonography
Middle Aged
Ventricular Dysfunction, Left / blood,  drug therapy,  ultrasonography
Ventricular Remodeling / drug effects*
Reg. No./Substance:
0/Aldosterone Antagonists; 0/Biological Markers; 52-39-1/Aldosterone; 976-71-6/Canrenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure.
Next Document:  Cardiac magnetic resonance of healthy children and young adults with frequent premature ventricular ...